组合疗法-话题@MedSci

#组合疗法#

36篇内容 | 1949人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1773054, encodeId=f7961e7305445, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=礼来携手勃林格殷格翰研发乳腺癌组合疗法, objectType=article, longId=73295, objectId=e152e3295c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e152e3295c3, replyNumber=0, likeNumber=137, createdTime=2017-03-12, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e152e3295c3, moduleTitle=礼来携手勃林格殷格翰研发乳腺癌组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e152e3295c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773055, encodeId=11d51e7305552, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=糖尿病患者福音！阿斯利康DPP4/SGLT2抑制剂组合疗法Qtern获欧盟批准, objectType=article, longId=73845, objectId=530de384583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=530de384583, replyNumber=0, likeNumber=66, createdTime=2017-02-26, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=530de384583, moduleTitle=糖尿病患者福音！阿斯利康DPP4/SGLT2抑制剂组合疗法Qtern获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=530de384583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773050, encodeId=6f461e7305076, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存, objectType=article, longId=67206, objectId=60226e206eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60226e206eb, replyNumber=0, likeNumber=96, createdTime=2016-08-31, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60226e206eb, moduleTitle=PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60226e206eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773051, encodeId=933a1e730519b, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=ASCO 2016：Selinexor组合疗法有望治疗复发且难治的多发性骨髓瘤, objectType=article, longId=70341, objectId=f48ae0341e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f48ae0341e9, replyNumber=0, likeNumber=69, createdTime=2016-07-16, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f48ae0341e9, moduleTitle=ASCO 2016：Selinexor组合疗法有望治疗复发且难治的多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f48ae0341e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773052, encodeId=5d5e1e73052a6, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=诺华联合卫材将在美国推出抗癌药Lenvima/Afinitor组合疗法, objectType=article, longId=70375, objectId=c875e0375c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c875e0375c6, replyNumber=0, likeNumber=79, createdTime=2017-02-22, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c875e0375c6, moduleTitle=诺华联合卫材将在美国推出抗癌药Lenvima/Afinitor组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c875e0375c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773048, encodeId=9f641e73048af, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=默沙东、Plexxikon强势携手打造肿瘤免疫组合疗法, objectType=article, longId=50549, objectId=9bdb5054940, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bdb5054940, replyNumber=0, likeNumber=75, createdTime=2015-12-01, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bdb5054940, moduleTitle=默沙东、Plexxikon强势携手打造肿瘤免疫组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bdb5054940)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773049, encodeId=f7ea1e7304964, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=俗解肿瘤免疫组合疗法, objectType=article, longId=54342, objectId=a8025434276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8025434276, replyNumber=0, likeNumber=72, createdTime=2015-09-01, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8025434276, moduleTitle=俗解肿瘤免疫组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8025434276)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773047, encodeId=d80f1e73047fa, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=罗氏、Exelixis计划向FDA提交治疗黑色素瘤新组合疗法, objectType=article, longId=44190, objectId=e8e54419036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8e54419036, replyNumber=0, likeNumber=60, createdTime=2015-12-02, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8e54419036, moduleTitle=罗氏、Exelixis计划向FDA提交治疗黑色素瘤新组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8e54419036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773044, encodeId=67d11e730448f, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=阿斯利康和Advaxis合作开发免疫肿瘤学组合疗法, objectType=article, longId=38199, objectId=460e38199d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=460e38199d1, replyNumber=0, likeNumber=91, createdTime=2014-09-28, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=460e38199d1, moduleTitle=阿斯利康和Advaxis合作开发免疫肿瘤学组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=460e38199d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773046, encodeId=c7db1e7304651, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=Ann Clin Transl Neurol：有效治疗ALS的新组合疗法, objectType=article, longId=43335, objectId=c95f43335cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c95f43335cb, replyNumber=0, likeNumber=89, createdTime=2015-08-05, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c95f43335cb, moduleTitle=Ann Clin Transl Neurol：有效治疗ALS的新组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c95f43335cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773043, encodeId=96f61e730434d, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=黑色素瘤Mekinist+Tafinlar组合疗法III期研究疗效显著提前终止（COMBI-v试验）, objectType=article, longId=38153, objectId=7ace381535b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ace381535b, replyNumber=0, likeNumber=62, createdTime=2014-09-03, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ace381535b, moduleTitle=黑色素瘤Mekinist+Tafinlar组合疗法III期研究疗效显著提前终止（COMBI-v试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ace381535b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773045, encodeId=c0a21e73045fe, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=Ann Clin Transl Neurol：有效治疗ALS的新组合疗法, objectType=article, longId=43312, objectId=6790433126e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6790433126e, replyNumber=0, likeNumber=72, createdTime=2015-05-21, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6790433126e, moduleTitle=Ann Clin Transl Neurol：有效治疗ALS的新组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6790433126e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773042, encodeId=36931e730428d, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=百时美计划启动免疫组合疗法大型III期试验, objectType=article, longId=31582, objectId=6842315820e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6842315820e, replyNumber=0, likeNumber=68, createdTime=2014-07-05, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6842315820e, moduleTitle=百时美计划启动免疫组合疗法大型III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6842315820e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773041, encodeId=43661e73041f5, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=Nat Biotechnol：研究开发出对抗癌症新组合疗法, objectType=article, longId=30928, objectId=bd3c309280f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd3c309280f, replyNumber=0, likeNumber=71, createdTime=2014-12-08, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd3c309280f, moduleTitle=Nat Biotechnol：研究开发出对抗癌症新组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd3c309280f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773040, encodeId=f3371e73040fb, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=辉瑞和GSK合作开展新颖组合疗法黑色素瘤I/II期试验, objectType=article, longId=27145, objectId=b3b22e14593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b22e14593, replyNumber=0, likeNumber=56, createdTime=2014-01-20, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b22e14593, moduleTitle=辉瑞和GSK合作开展新颖组合疗法黑色素瘤I/II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3b22e14593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773039, encodeId=9e481e7303910, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格, objectType=article, longId=24620, objectId=18ab2462050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ab2462050, replyNumber=0, likeNumber=69, createdTime=2014-04-06, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ab2462050, moduleTitle=FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18ab2462050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1773038, encodeId=fd161e730383e, content=<a href='/topic/show?id=38b7e76380a' target=_blank style='color:#2F92EE;'>#组合疗法#</a>, objectTitle=Blood：药物组合疗法有助治疗多发性骨髓瘤, objectType=article, longId=7065, objectId=2c77e065e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c77e065e9, replyNumber=0, likeNumber=73, createdTime=2013-01-26, rootId=0, userName=yankaienglish, userId=81db38453761, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c77e065e9, moduleTitle=Blood：药物组合疗法有助治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c77e065e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

组合疗法

2020-05-29

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

礼来携手勃林格殷格翰研发乳腺癌组合疗法

2017-03-12

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

糖尿病患者福音！阿斯利康DPP4/SGLT2抑制剂组合疗法Qtern获欧盟批准

2017-02-26

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存

2016-08-31

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

ASCO 2016：Selinexor组合疗法有望治疗复发且难治的多发性骨髓瘤

2016-07-16

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

诺华联合卫材将在美国推出抗癌药Lenvima/Afinitor组合疗法

2017-02-22

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

默沙东、Plexxikon强势携手打造肿瘤免疫组合疗法

2015-12-01

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

俗解肿瘤免疫组合疗法

2015-09-01

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

罗氏、Exelixis计划向FDA提交治疗黑色素瘤新组合疗法

2015-12-02

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

阿斯利康和Advaxis合作开发免疫肿瘤学组合疗法

2014-09-28

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

Ann Clin Transl Neurol：有效治疗ALS的新组合疗法

2015-08-05

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

黑色素瘤Mekinist+Tafinlar组合疗法III期研究疗效显著提前终止（COMBI-v试验）

2014-09-03

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

Ann Clin Transl Neurol：有效治疗ALS的新组合疗法

2015-05-21

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

百时美计划启动免疫组合疗法大型III期试验

2014-07-05

heli0118 (审核中...)

前往app查看评论内容

#组合疗法#

Nat Biotechnol：研究开发出对抗癌症新组合疗法

2014-12-08

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

辉瑞和GSK合作开展新颖组合疗法黑色素瘤I/II期试验

2014-01-20

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格

2014-04-06

yankaienglish (审核中...)

前往app查看评论内容

#组合疗法#

Blood：药物组合疗法有助治疗多发性骨髓瘤

2013-01-26

科室
- - 订阅+
  - 更多科室
工具
服务